<DOC>
	<DOCNO>NCT02874326</DOCNO>
	<brief_summary>The purpose study determine whether long-acting octreotide safe effective treatment patient Rendu-Osler-Weber ( e.g . HHT ) . The study hypothesis octreotide safe reduce transfusion requirement endoscopy frequency ROW patient refractory anaemia due bleed gastrointestinal telangiectasias .</brief_summary>
	<brief_title>Octreotide Patients With GI Bleeding Due Rendu-Osler-Weber</brief_title>
	<detailed_description>Rationale : Rendu-Osler-Weber ( ROW ) autosomal dominant hereditary disease affect 1 / 5-8000 individual . It characterize arteriovenous malformation ( AVMs ) telangiectasias multiple organ , include gastrointestinal tract . Patients transfusion dependent due severe gastrointestinal bleeding telangiectasias . Endoscopy effective due recurrent character telangiectasias . Based literature patient non-ROW AVMs telangiectasias , octreotide might beneficial patient decrease transfusion need . Objective : To assess efficacy octreotide decrease need transfusion endoscopic intervention patient ROW refractory anaemia due gastrointestinal bleeding telangiectasias . Study design : Multicenter , open-label uncontrolled pilot study . Study population : Patients ROW symptomatic gastrointestinal bleeding telangiectasias , transfusion and/or endoscopy dependent : 1 . Transfusion dependent : least 2 blood and/or iron infusion 6 month inclusion . 2 . Endoscopy dependent : least one endoscopic intervention argon plasma coagulation ( APC ) initial/first endoscopic treatment diagnosis half year inclusion unsuitable endoscopy . Intervention : The intervention 20 mg Sandostatin long-acting release ( LAR ) every four week 26 week top standard care . Main study parameters/endpoints : Primary outcome response treatment define : - complete : endoscopic intervention transfusion requirement - partial : reduction endoscopic intervention transfusion requirement - non-response : equal increase endoscopy frequency transfusion Important secondary outcome percent change number rebleeds baseline endpoint number epistaxis episode .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Gastrointestinal Hemorrhage</mesh_term>
	<mesh_term>Telangiectasia , Hereditary Hemorrhagic</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Patients RenduOslerWeber Symptomatic gastrointestinal bleeds telangiectasias Transfusion / endoscopy dependent : Transfusion : least 2 blood and/or iron infusion 6 month inclusion . Endoscopy : least one endoscopy APC initial endoscopic treatment diagnosis half year inclusion unsuitable endoscopic therapy . liver cirrhosis ChildPugh C acute liver failure previous unsuccessful treatment somatostatin analogue ( SST ) indication ( refractory anaemia due telangiectasias ) current effective treatment somatostatin analogue severe diseases life expectancy &lt; 1 year patient leave ventricular assist device ( LVAD 's ) Symptomatic cholecystolithiasis ( without cholecystectomy ) pregnancy nurse woman woman pregnancy wish study period use anticonception inadequate current chemotherapy patient know hypersensitivity SST analogues component octreotide LAR formulation understand Dutch English</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Sandostatin LAR</keyword>
	<keyword>Somatostatin</keyword>
	<keyword>Octreotide</keyword>
</DOC>